Evidence map›Paper›PMID 25289107›Full record

ArticleOncology letters2014

Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma.

Mariana Barbosa DE Souza, Otávio Alberto Curioni, Jossi Ledo Kanda, Marcos Brasilino DE Carvalho

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. MIF contribution to progressive brain diseases.Journal of neuroinflammation · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mariana Barbosa DE SouzaDepartment of Radiology and Oncology, Medical School, University of São Paulo, São Paulo 01246903, Brazil ; Laboratory of Molecular Biology, Heliópolis Hospital, São Paulo 04231030, Brazil.
Otávio Alberto CurioniLaboratory of Molecular Biology, Heliópolis Hospital, São Paulo 04231030, Brazil ; Department of Head and Neck Surgery and Otorhinolaryngology, Heliópolis Hospital, São Paulo 04231030, Brazil.
Jossi Ledo KandaDepartment of Head and Neck Surgery, Padre Anchieta Teaching Hospital, ABC Medical School, São Bernardo do Campo 09715090, Brazil.
Marcos Brasilino DE CarvalhoLaboratory of Molecular Biology, Heliópolis Hospital, São Paulo 04231030, Brazil ; Department of Head and Neck Surgery and Otorhinolaryngology, Heliópolis Hospital, São Paulo 04231030, Brazil.
Hospital São Paulo · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overexpression of macrophage migration inhibitory factor (MIF) has been identified in a variety of tumors and the investigation of its molecular mechanisms in tumor progression is a key topic of research. The present study aimed to investigate MIF as a potential marker for disease control or recurrence, and to assess the association between serum and salivary MIF and the clinicopathological characteristics of patients with oral squamous cell carcinoma (OSCC). Serum and salivary samples were collected prior to and following the surgical treatment of 50 patients with OSCC. MIF concentrations were assessed by enzyme-linked immunosorbent assay and the adopted level of statistical significance was P<0.05. The results revealed that serum MIF concentrations were significantly reduced following tumor resection in OSCC patients. Furthermore, higher preoperative salivary MIF concentrations were observed in patients with larger tumors and in those who succumbed to the disease. In conclusion, high salivary and serological MIF concentrations were identified in patients with OSCC. Nevertheless, only serological MIF concentrations may be considered as a potential marker for the early detection of OSCC recurrence once the salivary levels, prior and following treatment, do not show any significant differences.

Indexed as

inflammationmacrophage migration inhibitory factororal cancersalivary biomarkerserum biomarker

Identifiers

PMID25289107
PMCPMC4186499
OpenAlexW2080704665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.